Results of a multicenter evaluation of automated assays for measurement of apolipoproteins (apo) A-I and B with the Paramax#{174} analytical system are reported. Apo A-I and apo B response surface models were used to optimize concentrations of critical assay variables. Overall imprecision for apo A-I controls at concentrations of 1.01-1.61 g/L was 3.7-6.6%; overall imprecision for apo B controls at 1.00-1.61 gIL was 2.8-6.9%. There was no interference in ape A-I measurements. Albumin concentrations >59 g/L resulted in a negative interference, and collection in sodium heparin caused a positive interference in apo B results. Apo A-I and apo B assays demonstrated acceptable agreement with comparative methods, although the Paramax apo B assay had a negative bias with respect to comparison methods. In 116 healthy individuals, serum apo A-I ranged from 0.97 to 2.05 gIL and serum apo B ranged from 0.51 to 1.32 g/L.
lipoprotein ligands for extracellular receptors, structural components of lipoproteins, and cofactors for specific enzyme reactions in lipid metabolism (3, 4) . Apolipeproteins also provide immunogenicity to lipeproteins and, if their blood concentrations are abnormal, can be key factors in genetic disorders (4) . Results of numerous studies have demonstrated the utility of apelipoprotein measurements for identifying patients with, and at risk for, CAD (5) (6) (7) (8) (9) .
The two apelipoproteins of greatest clinical significance are A-I and B. Ape A-I is the major apolipoprotein of high-density lipeprotein (HDL). Concentrations of ape A-I and HDL-cholesterol (HDL-C) have been shown to correlate inversely with the risk of CAD (10). Ape B is the major apolipoprotein of low-density lipoprotein (LDL). Concentrations of ape B and LDL-C are correlated directly with increased risk of CAD (8). There is substantial evidence indicating that apelipoprotem measurements, particularly of ape A-I and ape B, may be more useful laboratory indices of CAD risk than measurements of HDL-C and LDL-C (7, (11) (12) (13) (14) (15) (16) . A further difficulty with LDL-C is that, in many laboratories, LDL-C concentrations may be approximated by a calculation (17) . However, clinical acceptance of apolipoprothin measurements stifi is somewhat restricted because of lack of comparability of results from different laboratories (4).
Immunological techniques are appropriate candidates for the determination of ape A-I and ape B concentrations, but the application of these techniques to apolipoprotein measurement is complex and presents several challenges to the laboratorian (18) . Use of immunoturbidimetric (19- PEG had the most effect on calibration curve size, with increasing amounts of PEG or antiserum increasing the curve size. The activator concentration had no effect on the response of purified ape A-I protein, which was used to assign the calibrators. The epitopes of the purified protein are probably easily accessible to the antiserum. The dynamic range is a complex function of antibody and activator.
The optimum point was found at the lowest concentration of activator and maximum concentration of Ab (see Fig. 1 PEG, antiserum, and sample size all had roughly similar effects of increasing the calibration curve range with increasing amounts. Although an actual prozone effect was not induced in these experimental evaluations, the response curve became less sensitive at high concentrations of ape B with increasing sample amount. Other variables were also important, especially a negative interactive term between antiserum and PEG. The correlation between these liquid solution conditions and the comparison method was acceptable over a wide formulation dynamic range for both normal and lipemic samples (data not shown). There was no significant effect on the r values from any variable.
Calibrator/Control Optimization

Calibrators
and controls for ape A-I were chosen for stabifity and compatibility with a variety of antisera. To investigate the latter criterion, we surveyed several commercially available calibrators for consistent recovery of serum values across different antisera. Four serum pools were chosen for high and low ape A-I and ape B concentrations.
The Dade CK/LD control was also used for recovery evaluation, since it appeared to respond in much the same way as a fresh serum specimen. The mean recovery of these five samples across three antisera lots from two different sources is ifiustrated for ape A-I in Table 2 
Assay Performance Characteristics
Results of precision studies conducted at each clinical site and the manufacturer (in-house) are listed in Table  3 . Apelipoprotein assay imprecision was evaluated at three (clinical sites) or two (manufacturer) concentra- Table   Table 4 . Interferences. Table 5 (Fig. 3A) or Beckman Array (Fig. 3B) Behring Apo A-I (gIL) The ECHIP software provided a large series of graphical representations of responses (response surfaces). We selected an example of an ape A-I response surface for the purpose of illustrating optimization of assay variables (Fig. 1) (Figs. 2 and 3) . As indicated in 
